Symbiotec Pharmalab IPO: Price Band, Steroid API Moat & GMP Review
A ₹1,450 Cr mainboard pharma issue specializing in high-margin steroid and hormone APIs. Full audit of global export market, financials and listing expectations.
The IPO this covers
ListedSymbiotec Pharmalab IPO · Mainboard
- GMP
- ₹185 (+18.72%)
- Price band
- ₹938 – ₹988
- Lot size
- 15 shares
- Bidding
- 24 Aug – 27 Aug
View live GMP, subscription & allotment dates →
* Info is indicative, not an investment advice.This analysis reviews the official Red Herring Prospectus (RHP), historical peer valuations, current exchange subscription trends, and grey market premium indicators. All figures are verified against official BSE, NSE, and SEBI regulatory filings.
Specialty active pharmaceutical ingredient (API) manufacturer Symbiotec Pharmalab Limited is closing its ₹1,450 Crore Mainboard IPO on 27 August 2026 with a price band of ₹938 to ₹988 per share.
Symbiotec is one of the few global manufacturers focused exclusively on complex steroid and hormone APIs, supplying top multinational pharmaceutical companies in over 40 countries.
1. Issue Overview
| Parameter | Details |
|---|---|
| Price Band | ₹938 to ₹988 per share |
| Lot Size | 15 Equity Shares |
| Minimum Retail Bid | ₹14,820 (1 Lot at cut-off) |
| Issue Size | ₹1,450 Crore |
| Closes On | 27 August 2026 |
| Allotment Date | 28 August 2026 |
| Listing Date | 1 September 2026 (NSE & BSE Mainboard) |
2. Business Moat: High-Barrier Steroid & Hormone APIs
Steroid and hormone API manufacturing requires USFDA and EU-GMP compliant dedicated facilities with stringent containment capabilities.
- USFDA Approved Plants: Operates advanced USFDA-inspected manufacturing units in Indore, Madhya Pradesh.
- Export Dominance: Over 70% of revenues are generated from regulated export markets including the US, Europe, and Japan.
- High Entry Barriers: Complex chemical synthesis processes make customer switching costs extremely high.
3. Financial Metrics & Valuation
| Financial Metric | FY24 | FY25 | FY26 (P) |
|---|---|---|---|
| Revenue from Operations | ₹620 Crore | ₹780 Crore | ₹960 Crore |
| EBITDA Margin | 24.5% | 26.8% | 28.2% |
| Net Profit (PAT) | ₹95 Crore | ₹135 Crore | ₹180 Crore |
At ₹988 upper band, the stock trades at ~24.5x FY26 P/E, presenting an attractive valuation compared to listed API peers like Divi's Laboratories (~60x P/E) and Solara Active Pharma.
Verdict
With strong USFDA compliance, high 28% EBITDA margins, and competitive pricing, Symbiotec Pharmalab IPO represents a solid fundamental pick for healthcare and pharma investors.
Disclaimer: Educational breakdown only. Please consult a SEBI-registered advisor.
Authored by IPOSathi Desk
Harshit is the Lead Primary Market Analyst at IPOSathi, tracking Indian initial public offerings, SME platforms, grey market movements, and corporate actions. All research is conducted independently with zero promoter compensation.
Frequently Asked Questions
What is the Symbiotec Pharmalab IPO price band and lot size?+
The price band is ₹938 to ₹988 per share with a lot size of 15 shares. Minimum application value is ₹14,820.
When does the Symbiotec Pharmalab IPO close?+
Public bidding closes on 27 August 2026, with allotment expected on 28 August 2026.
Recommended IPO Research & Guides
ESDS Software Solution IPO: 84% GMP, Price Band & Deep Financial Review
A ₹1,200 Cr mainboard cloud infrastructure IPO carrying an 84% grey market premium. Complete breakdown of business model, financials, risks and valuation.
NSE IPO Review & Valuation: Market Monopoly, Derivatives Volume Moat & BSE Comparison
India's exchange monopoly National Stock Exchange (NSE) prepares for its historic public listing. We audit its trading fee moats, SEBI circular impact, and unlisted valuation multiples.
Gala Precision Engineering IPO Review: ₹168 Cr Issue, Disc Springs Moat, Wind Turbine & EV Supply
Global high-precision spring and fastener specialist Gala Precision Engineering is launching its ₹168 Crore IPO. Complete breakdown of wind turbine disc spring dominance, export margins, and 45% GMP.
Tolins Tyres IPO Review: ₹230 Cr Issue, Tyre Retreading & 2W/3W Manufacturing Moat
Kerala-based tyre retreading compound and two/three-wheeler tyre manufacturer Tolins Tyres is launching its ₹230 Crore IPO. Full financial review, raw rubber pricing trends, and valuation.